Hepatitis B Incidence in Individuals with Chronic Kidney Disorder: A Meta-Analysis

Kumar Kumawat, Kumar Bansal, Lovely, Goyal, Srinath and Vashisht

Health Leadership and Quality of Life, 2025, vol. 4, 619

Abstract: The hepatitis B virus is a major contributor to liver disease and has many non-liver symptoms. In addition to the significant impairment and mortality that HBV causes in the population, the most recent study indicates the role that HBV plays in the initiation and development of Chronic Kidney Disease (CKD). The causal relationship between HBV and CKD has yet to be fully elucidated. Antiviral nucleos (t) medicine compounds for HBV are already available, and they are very effective for individuals with chronic kidney disease. An increased probability of CKD has been identified in those with HBV, according to a recent meta-analysis of clinical data. Based on the most recent review, we identified six separate clinical trials. There was too much variation to draw any firm conclusions. Several proposed reasons account for the increased risk of CKD in HBsAg optimistic patients. Additional data links treatment with nucleos(t)ide equivalents to a decreased risk of end-stage renal disease (ESRD) and links undiagnosed HBV to an increased risk of ESRD in the CKD population. They advise that kidney activity and urine alterations be measured at the outset and periodically in HBV participants.

Date: 2025
References: Add references at CitEc
Citations:

There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:dbk:health:v:4:y:2025:i::p:619:id:619

DOI: 10.56294/hl2025619

Access Statistics for this article

More articles in Health Leadership and Quality of Life from AG Editor
Bibliographic data for series maintained by Javier Gonzalez-Argote ().